Donald Trump’s pick to run HHS has been under fire for trading health care stocks but at least six Senators at his confirmation hearings also own such stocks.
Orphan drugs for rare diseases have helped or saved hundreds of thousands of patients like 2-year-old Luke Whitbeck, but families and insurers are picking up the astronomical cost.
Una investigación de Kaiser Health News analiza las acciones de compañias farmacéuticas para manipular los precios de medicamentos huérfanos, utilizados para tratar enfermedades raras.
Drugmakers have brought almost 450 orphan drugs to market and collected rich incentives but nearly a third of those products aren’t new or were repurposed multiple times, an investigation shows.
A breakdown of winners — and a few losers — in the sprawling Cures Act approved by the House.
Three lobbyists for every member of Congress in a push to pass a bill that increases research funding and speeds up approvals.
The FDA’s drug-approval team is short more than 700 people and losing skilled staff members to the drug industry.
In a report out tuesday, hospital groups said drug prices have skyrocketed since 2013, triggering a huge increase in what hospitals spend on pharmaceuticals.
Researchers examine the Food and Drug Administration’s “revolving door” regarding employees who worked on cancer and hematology drugs.
Four years after a huge push to speed generics to market, the FDA has more than 4,000 generics waiting for approval.